PsychostimulantthatdisplaysneuroprotectiveandantiparkinsonianactivityinaprimatemodelofParkinson'sdisease.Promotesvigilenceandwakefulnesswithoutthecentralandperipheralsideeffectsassociatedwithconventionaldopaminergicpsychostimulants.Mechanismofactionisnotfullyunderstood,possIBLyviamodulationofcatecholamine/GABAergicneurotransmission.
| M.Wt | 273.35 |
| Formula | C15H15NO2S |
| Storage | Storeat+4°C |
| Purity | ≥98%(HPLC) |
| CASNumber | 68693-11-8 |
| PubChemID | 4236 |
| InChIKey | YFGHCGITMMYXAQ-UHFFFAOYSA-N |
| Smiles | O=S(CC(N)=O)C(C2=CC=CC=C2)C1=CC=CC=C1 |
Thetechnicaldataprovidedaboveisforguidanceonly.ForbatchspecificdatarefertotheCertificateofAnalysis.
AllTocrisproductsareintendedforlaboratoryresearchuseonly.
| Solvent | MaxConc.mg/mL | MaxConc.mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 20.5 | 75 | |
| ethanol | 2.73 | 10 |
Thefollowingdataisbasedontheproductmolecularweight273.35.Batchspecificmolecularweightsmayvaryfrombatchtobatchduetosolventofhydration,whichwillaffectthesolventvolumesrequiredtopreparestocksolutions.
| Concentration/SolventVolume/Mass | 1mg | 5mg | 10mg |
|---|---|---|---|
| 1mM | 3.66mL | 18.29mL | 36.58mL |
| 5mM | 0.73mL | 3.66mL | 7.32mL |
| 10mM | 0.37mL | 1.83mL | 3.66mL |
| 50mM | 0.07mL | 0.37mL | 0.73mL |



